FDAnews Drug Daily Bulletin
Jan. 20, 2005 | Vol. 2 No. 14
Mylan Pharmaceuticals has confirmed that its proposed $4 billion acquisition of brand firm King Pharmaceuticals is in jeopardy.
The Institute of Medicine has issued a report recommending that dietary supplements be subject to much more stringent rules governing safety and effectiveness -- much in the same way prescription drugs are regulated.
The FDA's highly anticipated advisory committee meeting addressing the safety of Cox-2 inhibitors has been scheduled for Feb. 16-18.
Bristol-Myers Squibb (BMS) is selling its U.S. and Canadian consumer medicines business, the company recently confirmed.
Amid a national debate over how to reform scientific research and boost innovation, a leading voice for French biotechnology has been meeting with government ministers to help close France's biotech gap with the U.S. and Britain.
SOUTHERN RESEARCH INSTITUTE SPINS OUT NEW FOR-PROFIT DRUG DELIVERY COMPANY, BROOKWOOD PHARMACEUTICALS
Southern Research Institute today formally announced that it has launched a new for-profit company, Brookwood Pharmaceuticals, Inc., spinning out the Institute's 30-year old in-house drug delivery group which focuses on the development of time-release formulations for pharmaceuticals delivery.
KV Pharmaceutical has additional borrowing capacity with its lenders after amending its loan agreements late last month, it said in a regulatory filing.
AIN Pharmaciez has decided to acquire Rejoice and Rejoice Pharmacy by mid-March to April.
SA's medicine manufacturers have indicated that they would continue to sell medicines at the reduced prices stipulated by the disputed medicine-pricing regulations, until the Constitutional Court has given direction on the matter.
Biobase, the German specialist in commercial biological databases, announced today the successful acquisition of Proteome Inc., a wholly-owned subsidiary of Incyte Corporation.
Shire Pharmaceuticals Group, based in Britain, said it licensed its HIV compound SPD754 to Avexa Ltd., an Australian specialty anti-infectives company.
ADENOSINE ANNOUNCES COLLABORATION WITH ORTHO-McNEIL TO DEVELOP NOVEL ORAL DRUGS FOR DIABETES AND ASTHMA
Adenosine Therapeutics has signed a worldwide collaboration and option agreement with Ortho-McNeil Pharmaceutical to further develop A2B adenosine receptor antagonist compounds for the potential treatment of Type II diabetes, asthma and other disorders.
Neoprobe has formed a new subsidiary to develop technology that has shown promise treating diseases such as cancer and HIV.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.